HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Pilocarpinhydrochlorid
PILOCARPINE HCL · PILOCARPINE HYDROCHLORIDE · (3S,4R)-4,5-DIHYDRO-3-ETHYL-4-(1-METHYL-1H-IMIDAZOL-5-YLMETHYL)-2(3H)-FURANONE HYDROCHLORIDE · Salagen · Sanpilo · pilocar · pilocel · (3S,4R)-
Identifikatoren & physikalische Daten
| CAS No. | 54-71-7 |
|---|---|
| Summenformel | C11H17ClN2O2 |
| Durchschnittliche Molmasse | 244,72 g/mol |
| Monoisotopische Masse | 244,09785546 g/mol |
| SMILES | CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C.Cl |
| InChIKey | RNAICSBVACLLGM-GNAZCLTHSA-N |
| PubChem CID | 5909 |
| ChEMBL | CHEMBL1200330 |
| ChEBI | CHEBI:141029 |
| EC No. | 200-212-5 |
| DTXSID | DTXSID2041096 |
| Lokaler Name | Pilocarpinhydrochlorid |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 44,1 |
|---|---|
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 3 |
| Schwere Atome | 16 |
| Formalladung | 0 |
| Komplexität | 245 |
| Löslichkeit | >36.7 [ug/mL] (The mean of the results at pH 7.4)H2O: 100 mg/mLsoluble |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Schmelzpunkt | 202-205 °C(lit.) |
| Lagerbedingungen | 2-8°C |
| Aggregatzustand | powder |
| Farbe | white |
| Merck | 14,7424 |
| BRN | 4034491 |
| Stabilität | Hygroscopic |
| Hauptanwendungen | forensics and toxicologyveterinary |
| InChI | 1S/C11H16N2O2.ClH/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H31H/t8-,10-/m0./s1 |
| InChIKey | RNAICSBVACLLGM-GNAZCLTHSA-N |
| SMILES | Cl.CC[C@H]1[C@H](COC1=O)Cc2cncn2C |
| LogP (Verteilungskoeffizient) | -0.095 (est) |
| CAS Datenbank | 54-71-7(CAS DataBase Reference) |
| EPA chemische Informationen | Pilocarpine monohydrochloride (54-71-7) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH300 (64.2%): Fatal if swallowed [Danger Acute toxicity, oral]P260, P264, P270, P271, P284, P301+P316, P304+P340, P316, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 123 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Regulatorische Informationen | Pilocarpine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | IMAP assessments - 2(3H)-Furanone, 3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, monohydrochloride, (3S-cis)-: Human health tier I assessment |
| Hazard Classes and Categories | Acute Tox. 2 (64.2%) |
| Treatment | Overdosage should be treated with atropine titration (0. 5 mg to 1. 0 mg given subcutaneously or intravenously) and supportive measures to maintain respiration and circulation. Epinephrine (0. 3 mg to 1. 0 mg, subcutaneously or intramuscularly) may also be of value in the presence of severe cardiovascular depression or bronchoconstriction. (L1712) |
| Expositionspfade | Oraleye contact. There was a decrease in the rate of absorption of pilocarpine from SALAGEN Tablets when taken with a high fat meal by 12 healthy male volunteers |
| Toxizitätsübersicht | Pilocarpine is a cholinergic parasympathomimetic agent. It increase secretion by the exocrine glands, and produces contraction of the iris sphincter muscle and ciliary muscle (when given topically to the eyes) by mainly stimulating muscarinic receptors. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| F | 3-8-10 |
| Wassergefährdungsklasse (WGK) | 3 |
| TSCA-Inventar-Status | TSCA listed |
| UN-Transportnummer | UN 1544 6.1/PG 3 |
Anwendungen & Verwendung
Verwenden
(+)-Pilocarpine hydrochloride is a muscarinic M1 and M2 acetylcholine receptor agonist with pKB values of 5 and 3.7, respectively. Systemic administration of (+)-Pilocarpine hydrochloride is typically used as an animal model for temporal lobe epilepsy and can mimic the generation of complex partial seizures by producing changes in hippocampal neuron morphology, membrane properties, and synaptic responses.